These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 32196884)

  • 21. Kidney volume and plasma hepatocyte growth factor-transforming growth factor beta1 ratio among children with biliary atresia before and after liver transplantation: the reversibility of nephromegaly.
    Cheng CH; Tsau YK; Tsai IJ
    Am J Kidney Dis; 2005 Nov; 46(5):830-6. PubMed ID: 16253722
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TGF-beta1 expression and chronic allograft nephropathy in protocol kidney graft biopsy.
    Viklický O; Matl I; Voska L; Böhmová R; Jaresová M; Lácha J; Lodererová A; Stríz I; Teplan V; Vítko S
    Physiol Res; 2003; 52(3):353-60. PubMed ID: 12790768
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of treated bacterial infections within one month before living donor liver transplantation in adults.
    Hara T; Soyama A; Takatsuki M; Hidaka M; Carpenter I; Kinoshita A; Adachi T; Kitasato A; Kuroki T; Eguchi S
    Ann Transplant; 2014 Dec; 19():674-9. PubMed ID: 25536330
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Living donor liver transplant recipients achieve relatively higher immunosuppressant blood levels than cadaveric recipients.
    Trotter JF; Stolpman N; Wachs M; Bak T; Kugelmas M; Kam I; Everson GT
    Liver Transpl; 2002 Mar; 8(3):212-8. PubMed ID: 11910565
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transforming growth factor β1 polymorphisms and progression of graft fibrosis after liver transplantation for hepatitis C virus--induced liver disease.
    Eurich D; Bahra M; Boas-Knoop S; Lock JF; Golembus J; Neuhaus R; Neuhaus P; Neumann UP
    Liver Transpl; 2011 Mar; 17(3):279-88. PubMed ID: 21384510
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Model for End-Stage Liver Disease score does not predict patient or graft survival in living donor liver transplant recipients.
    Hayashi PH; Forman L; Steinberg T; Bak T; Wachs M; Kugelmas M; Everson GT; Kam I; Trotter JF
    Liver Transpl; 2003 Jul; 9(7):737-40. PubMed ID: 12827562
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peripheral blood biomarkers for the characterization of alloimmune reactivity after pediatric liver transplantation.
    Briem-Richter A; Leuschner A; Krieger T; Grabhorn E; Fischer L; Nashan B; Haag F; Ganschow R
    Pediatr Transplant; 2013 Dec; 17(8):757-64. PubMed ID: 24164827
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preoperative serum 25-hydroxyvitamin D
    Tan YL; Sun LY; Zhu ZJ; Wei L; Zeng ZG; Qu W; Liu Y; Zhang HM; Wang J; He EH; Xu RF; Zhang L
    Pediatr Pulmonol; 2020 Oct; 55(10):2683-2688. PubMed ID: 32501629
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of different immunosuppressive regimens on TGF-beta1 expression in kidney transplant patients.
    Matl I; Viklický O; Voska L; Lodererová A; Vítko S
    Transpl Int; 2005 Jun; 18(6):668-71. PubMed ID: 15910291
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Circulating TGF-β1 and VEGF and risk of cancer among liver transplant recipients.
    Engels EA; Jennings L; Kemp TJ; Chaturvedi AK; Pinto LA; Pfeiffer RM; Trotter JF; Acker M; Onaca N; Klintmalm GB
    Cancer Med; 2015 Aug; 4(8):1252-7. PubMed ID: 25919050
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytomegalovirus infection in living donor liver transplant recipients significantly impacts the early post-transplant outcome: A single center experience.
    Yadav SK; Saigal S; Choudhary NS; Saha S; Sah JK; Saraf N; Kumar N; Goja S; Rastogi A; Bhangui P; Soin AS
    Transpl Infect Dis; 2018 Aug; 20(4):e12905. PubMed ID: 29668120
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recurrent primary sclerosing cholangitis in the Adult-to-Adult Living Donor Liver Transplantation Cohort Study: Comparison of risk factors between living and deceased donor recipients.
    Gordon FD; Goldberg DS; Goodrich NP; Lok AS; Verna EC; Selzner N; Stravitz RT; Merion RM
    Liver Transpl; 2016 Sep; 22(9):1214-22. PubMed ID: 27339253
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transforming growth factor-beta1 in plasma and liver of children with liver disease.
    Rosensweig JN; Omori M; Page K; Potter CJ; Perlman EJ; Thorgeirsson SS; Schwarz KB
    Pediatr Res; 1998 Sep; 44(3):402-9. PubMed ID: 9727721
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of recipient size and allograft type on pediatric liver transplantation for biliary atresia.
    Alexopoulos SP; Nekrasov V; Cao S; Groshen S; Kaur N; Genyk YS; Matsuoka L
    Liver Transpl; 2017 Feb; 23(2):221-233. PubMed ID: 27862929
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes of liver transplantation for end-stage biliary disease: A comparative study with end-stage liver disease.
    Lai YH; Duan WD; Yu Q; Ye S; Xiao NJ; Zhang DX; Huang ZQ; Yang ZY; Dong JH
    World J Gastroenterol; 2015 May; 21(20):6296-303. PubMed ID: 26034365
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of alloreactivity and intragraft cytokine profiles in living donor liver transplant recipients with graft acceptance.
    Takatsuki M; Uemoto S; Inomata Y; Sakamoto S; Hayashi M; Ueda M; Kanematsu T; Tanaka K
    Transpl Immunol; 2001 Feb; 8(4):279-86. PubMed ID: 11316071
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk Factors Affecting Outcomes in Pediatric Liver Transplantation: A Real-World Single-Center Experience.
    Hong SK; Yi NJ; Hong K; Han ES; Lee JM; Choi Y; Lee KW; Suh KS
    Ann Transplant; 2021 May; 26():e929145. PubMed ID: 34045429
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Urinary transforming growth factor-beta1 excretion in renal allograft recipients during the early post-transplantation period.
    Goumenos DS; Tsakas S; Karavias D; Savidaki I; Karatzas T; Vlachojannis JG
    Ren Fail; 2003 Jul; 25(4):561-8. PubMed ID: 12911160
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term outcomes in pediatric liver recipients: comparison between cyclosporin A and tacrolimus.
    Cao S; Cox KL; Berquist W; Hayashi M; Concepcion W; Hammes GB; Ojogho OK; So SK; Frerker M; Castillo RO; Monge H; Esquivel CO
    Pediatr Transplant; 1999 Feb; 3(1):22-6. PubMed ID: 10359027
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Defining long-term outcomes with living donor liver transplantation in North America.
    Olthoff KM; Smith AR; Abecassis M; Baker T; Emond JC; Berg CL; Beil CA; Burton JR; Fisher RA; Freise CE; Gillespie BW; Grant DR; Humar A; Kam I; Merion RM; Pomfret EA; Samstein B; Shaked A
    Ann Surg; 2015 Sep; 262(3):465-75; discussion 473-5. PubMed ID: 26258315
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.